A Diary Of A Mesowarrior #Mesothelioma #Asbestos – Shut in with the Snow, Rare Disease Day -MIST Trial for Mesothelioma Announced
Tom Banbury
What a week its been. All we have talked about is snow that is the word on every ones lips this week.
The photos have been wonderful and we have a brilliant photographer her in Whistable.
He uses his drone and that means we have views that are just great. The one above is one and I was enthralled the snow goes up to the waterline. The edges were frozen as well.
The snow gets thicker the more we go out of Whistable but the roads have been treacherous.
We live in the country side so but was amazed that the roads
Were possible
There that is my photos we had to have snow pictures didn’t we.
Today has been Rare Disease D
ay
They call Mesothelioma rare I don’t understand why? But I suppose it’s because it is a hard one to conquer.
But the great news is that there is another trial for us this month. The MIST Trial.
British Lung Foundation is funding a ‘world-first’ clinical trial for mesothelioma. Patients in who chemo has failed, will be split into different treatment groups based on the characteristics of their tumours. The trial opens for recruitment next month. http://www.mesothelioma-research-leicester.com/mist/ @Leic_hospital
I have had emails everyday arranging for me to be free to speak in different conferences and meetings so my life is getting busier from now on. I seem to be travelling further afield so I just go with the flow.
This is the start of something big — Mesothelioma Stratified Therapy (MiST)
Drug based therapies are limited by variations in sensitivity within the population being treated. Some patients’ mesotheliomas are drug-sensitive, whilst others are resistant. In recent years, it has become clear that in order to maximize the benefit of anticancer drugs, a one-size-fits-all approach, is no longer applicable.
Identifying patients’ tumours likely to respond to a particular drug requires a predictive biomarker, coupled to a targeted therapy. So called, Personalised medicine. For patients with mesothelioma, personalised medicine is currently in its infancy.
With the support of a £2.5M donation from the British Lung Foundation, Leicester is leading the development of the world’s first molecularly stratified umbrella study, Mesothelioma Stratified Therapy (MisT).
This trial, set to open in the 1st quarter of 2018 will utilise as a first step, a molecular profiling panel to identify patients who are eligible for treatment. The second step will be to stratify patients for treatment, based on molecular eligibility. Patients would receive up to 4 different treatments sequentially. The third step will be to utilize genomic interrogation of the original biopsy tissue, in order to understand why patients respond (or not) to the trial drugs, and if they respond, what factors eventually lead to the emergence of drug resistance.
MiST will be a flagship, Leicester sponsored clinical trial. Initially located in a single centre, the expectation will be that the study will be able to expand to multiple UK centres, with the potential to add promising new treatment arms and additional molecular stratifications.
Very exciting things for 2018.
I start with a Conference The 12KBW have the Annual Conference where Ray and I will be giving a short speech about the MNFoundation.
We are delighted to announce our Annual Asbestos Seminar on 21 March 2018 at the Barbican Centre.
The seminar will be chaired by Harry Steinberg QC with talks from 2pm to 6pm and will be followed by a drinks reception.
Members of our team have continued to act in the leading cases, including Bussey v Anglia Heating Ltd, in which Michael Rawlinson QC and Gemma Scott presented a challenge to the decision of the Court of Appeal in Williams v University of Birmingham.
https://mailchi.mp/37ca8c21ae09/12kbw-annual-asbestos-seminar?e=8242ff64ec
from Rayandmave's Blog http://ift.tt/2HSmTRe
via IFTTT
Reviewed by Unknown
on
February 28, 2018
Rating:
No comments: